Skip to main content
. 2018 Jan 17;19(3):169–174. doi: 10.1080/15384047.2017.1414759

Table 3.

Efficacy analysis.

  Patient populatin
  n = 33
PFS (median/months) (95% CI) 11 (7.8–14.1))
Tumor response  
 Complete response 4 (%12)
 Partial response 2 (%6)
 Stable disease 10 (%30)
 Progressive disease 15 (%45)
 Mixed response 2 (%6)
OS (median/months) (95% CI) 21 (10.6–31.3)

PFS, progression free survival; OS, overall survival; CI, confidence interval